RPT-Cubist sales force seen as potential boon for Merck intestinal drug

Dec 9 (Reuters) - In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.